Sotac Pharmaceuticals

Sotac Pharmaceuticals EPS

Indtjening pr. aktie (EPS) for Sotac Pharmaceuticals (SOTAC.NS) pr. 22. okt. 2026 er 7,26 INR. I foregående år var Indtjening pr. aktie (EPS) 3,24 INR — en ændring på 124,25 % (højere).

EPS

7,26INR

YoY

124,25%

Senest opdateret:

Indtjening pr. aktie (EPS) for Sotac Pharmaceuticals er 2025 7,26 INR. Indtjening pr. aktie (EPS) for Sotac Pharmaceuticals var 2024 3,24 INR. Det falder dermed med 124,25% højere sammenlignet med året før.

Sotac Pharmaceuticals EPS historik

  • 3 år

  • 10 år

  • 25 år

  • Maks

EPS
Dato
EPS
1. jan. 2020
0,08 INR
1. jan. 2021
-2,14 INR
1. jan. 2022
2,61 INR
1. jan. 2023
4,07 INR
1. jan. 2024
3,24 INR
1. jan. 2025
7,26 INR
Sotac Pharmaceuticals EPS historik
ÅREPSYoY
7,26INR+124,25%
3,24INR-20,38%
4,07INR+56,17%
2,61INR-221,70%
-2,14INR-2.803,31%
0,08INR—

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Sotac Pharmaceuticals Aktieanalyse

Hvad laver Sotac Pharmaceuticals? Sotac Pharmaceuticals Ltd develops and manufactures pharmaceutical products under loan license or contract manufacturing agreements for various marketers. The company specializes in Non Beta-Lactam tablets, capsules, syrup, and external preparations, with a therapeutic portfolio covering Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, Anti-Pyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin products. Its subsidiaries SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience support its manufacturing and development activities. The company generates revenue by producing pharmaceutical products on a contract manufacturing basis for different marketers, who then market and sell these products under their own brands. Sotac Pharmaceuticals' manufacturing services are utilized by various marketers seeking to outsource production without maintaining their own facilities. The firm's focus on a diverse therapeutic portfolio ensures consistent demand across multiple healthcare segments. Sotac Pharmaceuticals' manufacturing capabilities are tailored to meet the specific requirements of its marketer clients, offering both Non Beta-Lactam and Beta-Lactam product lines. The company's subsidiaries provide additional support in healthcare, research, and lifescience sectors, enhancing its overall service offerings. Its product range spans from basic medications like Anti-Cold and Anti-Allergic to specialized treatments such as Anti-Fungal and Cephalosporin antibiotics. Sotac Pharmaceuticals er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Sotac Pharmaceuticals aktie

Indtjening pr. aktie (EPS) for Sotac Pharmaceuticals er 7,26 INR i 2025.

Indtjening pr. aktie (EPS) for Sotac Pharmaceuticals ændrede sig fra 3,24 INR til 7,26 INR, hvilket repræsenterer en ændring på 124,25 %. Værdien er højere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af Indtjening pr. aktie (EPS) Sotac Pharmaceuticals siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

Indtjening pr. aktie måler den del af virksomhedens fortjeneste, der er allokeret til hver udestående aktie, og er en nøglekenntal til vurdering af en virksomheds rentabilitet pr. aktie.

EPS = Nettoindtjening / Udestående aktier

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Resultatopgørelse — Sotac Pharmaceuticals

Alle nøgletal — Sotac Pharmaceuticals